POLISH FINANCIAL SUPERVISION AUTHORITY
UNI - EN REPORT No6/2017
Date of issue:2017-02-13
Short name of the issuer
SOPHARMA AD
Subject
Notification for signed contract for merger between Sopharma AD and Medica AD
Official market - legal basis
art. 17. 1 MAR.
Unofficial market - legal basis
Contents of the report:
Sopharma AD (the “Company”) notifies that on 13 February 2017 the Contract for merger, as well as reports of the management bodies of the companies involved in the transformation of the company under art. 262i of the CA and the report of the examiner under art. 262m of the CA for transformation through merger between Sopharma AD, Sofia, UIC 831902088 and Medica AD, Kazanluk, UIC 000000993 were filed with the FSC for approval pursuant to art. 124, par. 1 of the Public Offering of Securities Act (POSA). As a result of the merger, all assets of Medica AD shall be transferred to Sopharma AD and the latter shall become its legal successor. Medica AD shall be terminated without liquidation. As a result of the merger, all shareholders of the transferring company Medica AD, with the exception of the receiving company Sopharma AD, which is also a shareholder of the transferring company, will receive shares of Sopharma AD and become shareholders of it. Against one share of Medica AD each shareholder pursuant to art. 261b, app. 1 of the CA shall receive 0.9486 treasury shares of the capital of Sopharma AD. All other conditions concerning the merger procedure are included in the Contract.
Annexes
FileDescription
uved vlivane Medika v KFN en.docNotification for signed contract for merger between Sopharma AD and Medica AD
SOPHARMA AD
(fullname of the issuer)
SOPHARMA ADFarmaceutyczny (far)
(short name of the issuer)(sector according to clasification of the WSE in Warsow)
1220Sofia
(post code)(city)
IlienskoShosse16
(street)(number)
+359 2 813 42 00+359 2 936 02 86
(phone number)(fax)
(e-mail)(web site)
nd
(NIP)(REGON)
SIGNATURE OF PERSONS REPRESENTING THE COMPANY
DateNamePosition / FunctionSignature
2017-02-13Ognian DonevExecutive director
uved vlivane Medika v KFN en.doc